KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy

Support Care Cancer. 2016 Feb;24(2):523-528. doi: 10.1007/s00520-015-2793-7. Epub 2015 Jun 24.

Abstract

Purpose: Low Karnofsky performance status (KPS) and elevated lactate dehydrogenases (LDHs) as a surrogate marker for tumor load and cell turnover may depict patients with a very short life expectancy. To validate this finding and compare it to other indices, namely, the recursive partitioning analysis (RPA) and diagnosis-specific graded prognostic assessment (DS-GPA), a multicenter analysis was undertaken.

Methods: A retrospective analysis of 234 metastatic melanoma patients uniformly treated with palliative whole brain radiotherapy (WBRT) was done. Univariate and multivariate analyses were used to determine the impact of patient-, tumor-, and treatment-related parameters on overall survival (OS).

Results: KPS and LDH emerged as independent factors predicting OS. By combining KPS and LDH values (KPS/LDH index), groups of patients with statistically significant differences in median OS (days; 95 % CI) after onset of WBRT were identified: group 1 (KPS ≥ 70/normal LDH) 234 (96-372), group 2 (KPS ≥ 70/elevated LDH) 112 (69-155), group 3 (KPS <70/normal LDH) 43 (12-74), and group 4 (KPS <70/elevated LDH) 29 (17-41). Between all four groups, statistically significant differences were observed. The RPA and DS-GPA indices failed to distinguish significantly between good and moderate prognosis and were inferior in predicting a very unfavorable prognosis.

Conclusions: The parameters KPS and LDH independently impacted on OS. The combination of both (KPS/LDH index) identified patients with a very short life expectancy, who might be better served by recommending best supportive care instead of WBRT. The KPS/LDH index is simple and effective in terms of time and cost as compared to other prognostic indices.

Keywords: Brain metastasis; LDH; Melanoma; Prognostic score; WBRT.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism
  • Brain / pathology
  • Brain Neoplasms / prevention & control*
  • Brain Neoplasms / radiotherapy*
  • Brain Neoplasms / secondary
  • Female
  • Humans
  • Karnofsky Performance Status*
  • Lactate Dehydrogenases / metabolism*
  • Male
  • Melanoma / pathology*
  • Melanoma / radiotherapy
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Retrospective Studies
  • Tumor Burden
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Lactate Dehydrogenases